Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness

Inclusion Criteria: * Understands nature and provision of the study * Have been informed about the study by the investigator and gave signed and dated informed consent prior to participation * Muscle soreness with a pain score of at least 3 on a 10 point categorical pain scale at 12-16h after exercise * Male and female subjects * Age 18-55 years * Subjects in good health as determined by the Investigator * Woman of childbearing potential using reliable methods of contraception with a low failure rate (i.e. less than 1% per year), e.g. implants, injectables, combined oral contraceptives, reliable intrauterine-devices, vasectomised/ infertile partner or surgically sterile (uterus removed or both tubes tied) or postmenopausal (at least 2 years without periods) Exclusion Criteria: * 4.2.1 General Exclusion Criteria * Investigator or any other team member involved directly or indirectly in the conduct of the clinical trial * Subjects who are inmates of psychiatric wards, prisons, or other state institutions * Participation in another clinical trial within the last 30 days and during the study * Not willing to refrain from exposing target areas after treatment to excessive ultraviolet light (solar radiation or solarium) * Pregnancy or lactation 4.2.2 Medical History Related Exclusion Criteria * History of dermal allergic reactions * Known hypersensitivity or allergy (including photoallergy) to NSAID´s including ketoprofen, and ingredients used in pharmaceutical products * Alcohol or drug abuse * Malignancy within the past 2 years * Skin lesions, dermatological diseases or tattoo in the treatment area * Major surgery 3 months before enrolment * NSAID idiosyncrasy * Impaired haematopoesis and coagulation * Gastric and duodenal ulcer and gastrointestinal bleedings * Systemic lupus erythematodes, mixed connective tissue disease * Major heart disease / uncontrolled hypertension * Hepatic failure with ALT and/or AST \> 2.0 ULN * Renal failure with serum creatinine levels \> 1.5 milligrams/deciliter (mg/dL) * Varicosis, thrombophlebitis and other vascular disorders of the lower extremities * Major traumatic lesions (e.g. fracture, tendon or muscle ruptures) of the musculo-sceletal system of the lower limbs * HIV - Infection * Hepatitis B or C * Asthma bronchiale * Blood donation one month before screening and during study